Use of Longidaza® in chronic prostatitis: A systematic review and meta-analysis

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Chronic bacterial prostatitis (CBP) is a disease with a multifaceted pathophysiological basis, including infectious, immunological, neurological, vascular, endocrinological, biochemical, and psychological factors, making it a multidisciplinary problem. One current treatment strategy is the use of the original drug Longidaza®, which has demonstrated efficacy in this disease, primarily due to its anti-inflammatory effect. A large number of original studies necessitate systematization of the results.

Objective. To conduct a comprehensive assessment of the clinical efficacy of Longidaza® (bovhyaluronidase azoximer) when included in the treatment plan for chronic prostatitis, based on data from controlled clinical trials.

Materials and Methods. A systematic review and meta-analysis were conducted according to the PRISMA protocol. Elibrary, PubMed, and Cyberleninka databases were used to search for articles. The search was conducted using a combination of keywords: chronic prostatitis and «Longidaza,» «Bovhyaluronidase azoximer,» among studies published no later than August 31, 2025.

Results. A search of scientific databases using the algorithms illustrated in Figure 1 yielded a total of 210 publications, of which 10 studies were then selected based on inclusion/exclusion criteria.

Conclusions. The results of the analysis suggest that adding Longidaza® to standard therapy for chronic prostatitis (antimicrobial and anti-inflammatory agents) significantly reduces clinical manifestations of the disease. Furthermore, the inclusion of Longidaza® in the treatment plan reduces inflammation in the prostate gland and improves maximum urinary flow rate, resulting in a significant reduction in the severity of chronic prostatitis.

全文:

受限制的访问

作者简介

Khalid Ibishev

Rostov State Medical University of the Ministry of Health of Russia

编辑信件的主要联系方式.
Email: Ibishev22@mail.ru
ORCID iD: 0000-0002-2954-842X

Doctor of Medical Sciences, Professor, Department of Urology and Human Reproductive Health (Course of Pediatric Urology-Andrology)

俄罗斯联邦, Rostov-on-Don

参考

  1. Kogan M.I., Ibishev H.S., Belousov I.I., Naboka Yu.L. Prostatitis and mimic diseases. Clinical reviews. M.: Medkongress, 2019, 300 p. Russian (Коган М.И., Ибишев Х.С., Белоусов И.И., Набока Ю.Л. простатит и заболевания-имитаторы. Клинические разборы. М.: Медконгресс, 2019, 300 с.)
  2. Lam JC, Stokes W. Acute and Chronic Prostatitis. Am Fam Physician. 2024 Jul;110(1):45-51.
  3. Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016 Jan 15;93(2):114-20.
  4. Kogan MI, Ibishev KS, Naboka YL, Gudima IA, Ferzauli AK, Ismailov RS, Naber KG. Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated. Investig Clin Urol. 2022 May;63(3):325-333.
  5. Kogan MI, Naboka YuL, Ismailov RS. Microbiota of prostatic secretion: comparative analysis of chronic prostatitis categories II and IIIA. Urologiia. 2020;(2):16–22. Russian (Коган М.И., Набока Ю.Л., Исмаилов Р.С. Микробиота простатического секрета: сравнительный анализ хронического простатита II и IIIA категории. Урология. 2020;(2): 16–22.)
  6. Stamatiou K, Pierris N. Mounting resistance of uropathogens to antimicrobial agents: A retrospective study in patients with chronic bacterial prostatitis relapse. Investig Clin Urol. 2017 Jul;58(4):271-280.
  7. Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D, Alivizatos G, Giamarellou E. Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019 May 1;74(5):1430-1437.
  8. Stamatiou K, Magri V, Perletti G, Papadouli V, Recleiti N, Mamali V, Zarkotou O. Chronic prostatic infection: Microbiological findings in two Mediterranean populations. Arch Ital Urol Androl. 2019 Oct 2;91(3).
  9. Ibishev Kh.S., Naboka Yu.L., Ismailov R.S. et al. Taxonomic characteristics and sensitivity to antibacterial drugs of microorganisms verified in the prostatic secretion of patients with chronic recurrent prostatitis who had COVID-19. Urology. 2023; 6:51-57. Russian (Ибишев Х.С., Набока Ю.Л., Исмаилов Р.С. и др. Таксономическая характеристика и чувствительность к антибактериальным препаратам микроорганизмов, верифицированных в секрете предстательной железы у пациентов с хроническим рецидивирующим простатитом, перенесших COVID-19. Урология. 2023;6:51-57).
  10. Wu Y, Jiang H, Tan M, Lu X. Screening for chronic prostatitis pathogens using high-throughput next-generation sequencing. Prostate. 2020 May;80(7):577-587.
  11. Xiong S, Liu X, Deng W, Zhou Z, Li Y, Tu Y, Chen L, Wang G, Fu B. Pharmacological Interventions for Bacterial Prostatitis. Front Pharmacol. 2020 Apr 30; 11:504.
  12. Papeš D, Pasini M, Jerončić A, Vargović M, Kotarski V, Markotić A, Škerk V. Detection of sexually transmitted pathogens in patients with chronic prostatitis/chronic pelvic pain: a prospective clinical study. Int J STD AIDS. 2017 May;28(6):613-615.
  13. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. Diagnostic and Management Strategies for Patients with Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Drugs Aging. 2021 Oct;38(10):845-886.
  14. Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010 Aug 15;82(4):397-406.
  15. Ibishev H. S., Cherny A. A., Kogan M. I. Clinical features of the course of chronic bacterial prostatitis against the background of testosterone deficiency. Bulletin of Urology. 2013;1:39-45. Russian (Ибишев Х.С., Черный А.А., Коган М.И. Клинические особенности течения хронического бактериального простатита на фоне дефицита тестостерона. Вестник урологии. 2013;1:39-45).
  16. Lam J.C., Lang R., Stokes W. How I manage bacterial prostatitis. Clin Microbiol Infect. 2023 Jan;29(1):32-37.
  17. Krayniy P.A., Ibishev H.S. Evaluation of immunological disorders in the prostatic secretion of patients with chronic recurrent bacterial prostatitis by electron microscopy. Urologiia. 2021;4:68–72. Russian (Крайний П.А., Ибишев Х.С. Оценка электронной микроскопией иммунологических нарушений в секрете предстательной железы пациентов с хроническим рецидивирующим бактериальным простатитом. Урология. 2021;4:68–72).
  18. Instructions for the medical use of the drug Longidaza LP-No. (009588)-(RG-RU)-040425. Russian (Инструкция по медицинскому применению лекарственного препарата Лонгидаза ЛП-№(009588)-(РГ-RU)-040425).
  19. Morozov AO, Vovdenko SV, Bragina EE, Boldyreva MN, Mhitaryan OA, Zubkov DA et al. GG01-31 A randomized controlled trial of bovhyaluronidase azoximer impact on biofilms in ejaculate of patients with chronic prostatitis and infertility. J Urol. 2025;213(5S).
  20. Lai HH, Pontari MA, Argoff CE, Bresler L, Breyer BN, Chou R et al. Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach. J Urol. 2025;214(2):116–26.
  21. Loran OB, Segal AS. System of summary assessment of symptoms in chronic prostatitis. Urologiia. 2001;(5):16–19. Russian (Лоран О.Б., Сегаль А.С. Система суммарной оценки симптомов при хроническом простатите. Урология. 2001;(5):16–19.
  22. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. // Cham: Springer International Publishing; 2015.
  23. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Newark: John Wiley & Sons, Incorporated; 2019.
  24. Pushkar D.Yu. Zaitsev A.V., Segal A.S. Longidaza in the treatment of chronic prostatitis. Urology. 2006;6:26-28. Russian (Пушкарь, Д.Ю. Зайцев А.В., Сегал А.С. Лонгидаза в лечении хронического простатита. Урология. 2006;6:26-28).
  25. Avdoshin V.P., Andryukhin M.I., Mikhailikov T.G. Magnetolaser and anti-sclerotic therapy in the complex treatment of patients with chronic bacterial prostatitis. Laser medicine. 2008;12(3):4–10. Russian (Авдошин В.П. Андрюхин М.И., Михайликов Т.Г. Магнитолазерная и антисклеротическая терапия в комплексном лечении больных хроническим бактериальным простатитом. Лазерная медицина. 2008;12(3):4–10).
  26. Solikhov D.N. Comparative assessment of modern methods of treatment of patients with chronic prostatitis: specialty 14.01.23 «Urology» // dissertation for the degree of Doctor of Medical Sciences. St. Petersburg, 2010. 210 p. Russian (Солихов Д.Н. Сравнительная оценка современных методов лечения больных хроническим простатитом: специальность 14.01.23 «Урология» // диссертация на соискание ученой степени доктора медицинских наук. Санкт-Петербург, 2010. 210 с.).
  27. Avdoshin VP, Andryukhin MI, Pulbere SA, Makarov OV, Mikhailikov TG. Evaluation of clinical efficacy of Longidaza® in combination treatment of patients with chronic prostatitis. Effective Pharmacotherapy. 2012;(43):22–5. Russian (Авдошин В.П., Андрюхин М.И., Пульбере С.А., Макаров О.В., Михайликов Т.Г. Оценка клинической эффективности препарата Лонгидаза® в комплексном лечении больных хроническим простатитом. Эффективная фармакотерапия. 2012;(43):22–25).
  28. Mkrtchyan AM, Kaisinova AS, Kocharyan GV. Balneopeloido- and Lymphotropic Therapy in Medical Rehabilitation of Patients with Chronic Prostatitis. Spa Medicine. 2015;(1):70–5. Russian (Мкртчян А.М., Кайсинова А.С., Кочарян Г.В. Бальнеопелоидо- и лимфотропная терапия в медицинской реабилитации больных хроническим простатитом. Курортная медицина. 2015;(1):70–5).
  29. Batkaev EA, Urpin MV. Improvement of complex therapy of chronic bacterial prostatitis. Bulletin of Postgraduate Medical Education. 2016;(1):24–30. Russian (Баткаев Э.А., Урпин М.В. Совершенствование комплексной терапии хронического бактериального простатита. Вестник последипломного медицинского образования. 2016;(1):24–30).
  30. Kulchavenya EV, Shvetsova OP, Breusov AA. Rationale for the use and efficacy of Longidaza in patients with chronic prostatitis. Urology. 2018;4:64–71. Russian (Кульчавеня Е.В., Швецова O.П., Бреусов A.A. Обоснование назначения и эффективность препарата Лонгидаза у больных хроническим простатитом. Урология. 2018;4:64–71).
  31. Mkrtchyan AM, Efimenko AP. Lymphotropic Therapy in a Complex of Rehabilitation Measures in Patients with Chronic Prostatitis. Bulletin of Physiotherapy and Spa Treatment. 2018; 24(3):112–4. Russian (Мкртчян А.М., Ефименко А.П. Лимфотропная терапия в комплексе реабилитационных мероприятий у пациентов хроническим простатитом. Вестник физиотерапии и курортологии. 2018;24(3):112–4).
  32. Seidov S-K. S-S., Asfandiyarov F.R., Kruglov V.A., Seidova S-Kh.S-K. Anti-sclerotic therapy of chronic prostatitis by rectal electrophoresis. Experimental and Clinical Urologiia. 2025;18(1):76–83. Russain (Сеидов С-К.С-С., Асфандияров Ф.Р., Круглов В.А., Сеидова С-Х.С-К. Антисклеротическая терапия хронического простатита методом ректального электрофореза. Экспериментальная и клиническая урология. 2025;18(1):76–83).

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Graphical diagram of a systematic review of research

下载 (367KB)
索引源数据
3. Fig. 2. Monitoring the severity of symptoms of chronic prostatitis. Forest graph and sensitivity analysis

下载 (180KB)
索引源数据
4. Fig. 3. Monitoring of leukocyte levels. Forest graph and sensitivity analysis

下载 (177KB)
索引源数据
5. Fig. 4. Monitoring of uroflowmetry data. Forest graph and sensitivity analysis

下载 (123KB)
索引源数据

版权所有 © Bionika Media, 2025